Therapeutic approaches aimed at disrupting this immunoregulatory axis—such as the monoclonal anti-CCR4 antibody mogamulizumab and small-molecule CCR4 antagonists including FLX475 and CCR4-351—have shown promise in restoring anti-tumor immunity. This evidence concerns the gene CCR4 and neoplasm.